心力衰竭中的抗栓药物
Antithrombotics in heart failure.
作者信息
Miličić Davor, Samardžić Jure, Petričević Mate
机构信息
Jure Samardzic, Department for Cardiovascular Diseases, University Hospital Center Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia,
出版信息
Croat Med J. 2014 Dec;55(6):621-7. doi: 10.3325/cmj.2014.55.621.
Heart failure is a common clinical condition associated with high morbidity and mortality rate despite significant improvements in pharmacotherapy and implementation of medical procedures. Patients with heart failure are at an increased risk of developing arterial and venous thrombosis, which contribute to the high rate of adverse events and fatal outcomes. Many heart failure patients routinely receive antithrombotic therapy due to the presence of a specific indication for its use, like ischemic heart disease or atrial fibrillation. However, there is no solid evidence to support the routine use of antithrombotic agents in all heart failure patients. This article reviews the evidence for using antithrombotic therapy in heart failure patients.
尽管药物治疗有了显著改善且实施了医疗程序，但心力衰竭仍是一种常见的临床病症，其发病率和死亡率很高。心力衰竭患者发生动脉和静脉血栓形成的风险增加，这导致了高不良事件发生率和致命后果。由于存在使用抗血栓治疗的特定指征，如缺血性心脏病或心房颤动，许多心力衰竭患者常规接受抗血栓治疗。然而，没有确凿证据支持在所有心力衰竭患者中常规使用抗血栓药物。本文综述了在心力衰竭患者中使用抗血栓治疗的证据。
Zotero 插件